Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells
Authors:
Preprint
Abstract
Despite the success of BCMA-targeting CAR-Ts in multiple myeloma, patients with high-risk cytogenetic features still relapse most quickly and are in urgent need of additional therapeutic options. Here, we identify CD70, widely recognized as a favorable immunotherapy target in other cancers, as a specifically upregulated cell surface antigen in high risk myeloma tumors. We use a structure-guided design to define a CD27-based anti-CD70 CAR-T design that outperforms all tested scFv-based CARs, leading to >80-fold improved CAR-T expansion in vivo. Epigenetic analysis via machine learning predicts key transcription factors and transcriptional networks driving CD70 upregulation in high risk myeloma. Dual-targeting CAR-Ts against either CD70 or BCMA demonstrate a potential strategy to avoid antigen escape-mediated resistance. Together, these findings support the promise of targeting CD70 with optimized CAR-Ts in myeloma as well as future clinical translation of this approach. One sentence summary Structure-optimized CD27-based CAR-T cells targeting CD70 are a promising therapeutic option for high-risk multiple myeloma patients who are most likely to relapse on current BCMA-targeting cellular therapies.Keywords
All Related Versions
- Published version: Blood.
This publication has 58 references indexed in Scilit:
- Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomicsCancer Immunology, Immunotherapy, 2023
- CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistanceCancer Cell, 2023
- Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemiaCancer Cell, 2022
- Structural delineation and phase-dependent activation of the costimulatory CD27:CD70 complexJournal of Biological Chemistry, 2021
- Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysisLeukemia, 2020
- Flex ddG: Rosetta Ensemble-Based Estimation of Changes in Protein–Protein Binding Affinity upon MutationThe Journal of Physical Chemistry B, 2018
- Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AMLCancer Cell, 2017
- Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9Nature Biotechnology, 2016
- CD70: An emerging target in cancer immunotherapyPharmacology & Therapeutics, 2015
- Pax5: the guardian of B cell identity and functionNature Immunology, 2007